About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Viewpoint - ATHA Energy Corp. has entered into definitive option agreements with Terra Uranium Ltd. allowing T92 to acquire a 70% interest in ATHA's Spire and Horizon properties, while ATHA can earn up to a 60% interest in T92's Pasfield Lake property [1] Spire Horizon Option - T92 is required to incur a minimum of $4,750,000 in exploration expenditures to earn a 70% interest in the Spire Horizon Projects, with specific expenditure milestones set for December 2024, September 2025, September 2026, September 2027, and September 2028 [2] - Upon meeting the first three expenditure milestones, a joint venture will be formed with T92 and ATHA each holding a 50% participating interest, which will adjust to 70% for T92 and 30% for ATHA after the fourth and fifth expenditures [3] Pasfield Option - T92 grants ATHA four separate options to acquire interests in the Pasfield Project, each requiring specific exploration expenditures or successful drilling activities to earn a 15% interest [4][5] - After exercising all Pasfield Options, ATHA can convert its interests into a 1% net smelter returns royalty, with a maximum of 4% [6] - A joint venture will be formed on the Pasfield Project upon completion of the fourth option, with T92 holding an initial 40% interest and ATHA holding 60% [6] Investor Relations Agreements - ATHA has extended its agreement with Hybrid Financial Inc. for an additional three months, and has also extended its agreement with Gold Standard Media LLC for three months, subject to TSX Venture Exchange approval [7] - The marketing campaign with Creative Direct Marketing Group Inc. has been deferred due to market conditions, with no additional costs incurred beyond an initial fee [7] Company Overview - ATHA Energy Corp. is focused on the acquisition, exploration, and development of uranium assets, holding a portfolio that includes three 100%-owned post-discovery uranium projects and the largest cumulative prospective exploration land package exceeding 8.5 million acres in prominent uranium basins [9]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team operates from key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - Proactive focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2] Group 2 - The company specializes in various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [2] - Proactive adopts technology to enhance workflows and improve content production [3] - All content published by Proactive is edited and authored by humans, ensuring adherence to best practices in content production and search engine optimization [3]

ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected by year end 2024 and commencement of dosing of ALS patients expected in 2025  Company announces cost containment measures in alignment with focus on advancing ATH-1105 BOTHELL, Wash., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal he ...

Company Overview - Athira Pharma, Inc. (ATHA) shares fell 72.2% in after-hours trading on September 3 due to disappointing results from the phase II/III LIFT-AD study for its candidate fosgonimeton in treating mild-to-moderate Alzheimer's disease (AD) [1] - The LIFT-AD study did not meet its primary endpoint, the Global Statistical Test (GST), which combines cognition and function measures [1] - Key secondary endpoints related to cognition, function, plasma biomarkers of neurodegeneration, protein pathology, and neuroinflammation were also not met [1] Study Results - In pre-specified subgroups of moderate AD patients or APOE4 gene carriers, cognition and function showed improvement or stabilization with fosgonimeton compared to placebo [2] - Prespecified biomarker analyses indicated that cognition and function, key measures of GST, favored treatment with fosgonimeton over placebo [2] Alzheimer's Disease Market - Biogen and Eisai's Leqembi received FDA approval for early AD treatment in July 2023, with expectations for blockbuster sales due to significant unmet needs in the AD market [3] - Eli Lilly's Kisunla (donanemab) was approved by the FDA in July 2024, making it the second drug available for early symptomatic AD [4] - Other companies, including Prothena Corporation, AC Immune, and Cassava Sciences, are also developing therapies for Alzheimer's disease [4] Stock Performance - Athira has seen a 16.4% increase in shares year-to-date, outperforming the industry growth of 0.6% [1] - Athira currently holds a Zacks Rank 2 (Buy) [5] - Illumina, Inc. (ILMN) is highlighted as a top-ranked stock in the biotech sector with a Zacks Rank 1 (Strong Buy) [5]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Group 1 - Athira Pharma, Inc. (ATHA) is currently ranked 2 (Buy) in the Zacks Rank system, indicating strong potential for outperforming the market in the next one to three months [1] - The Zacks Consensus Estimate for ATHA's full-year earnings has increased by 8.2% over the past quarter, reflecting improved analyst sentiment and earnings outlook [2] - Year-to-date, ATHA has gained approximately 28%, significantly outperforming the average gain of 11.1% for stocks in the Medical group [2] Group 2 - Athira Pharma, Inc. is part of the Medical - Biomedical and Genetics industry, which consists of 497 companies and is currently ranked 84 in the Zacks Industry Rank [3] - The Medical - Biomedical and Genetics industry has seen an average gain of 1.9% this year, indicating that ATHA is performing better than its industry peers [3] - HCA Healthcare, another notable stock in the Medical sector, has returned 41.5% year-to-date and is ranked 1 (Strong Buy) in the Zacks Rank [2][3]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...